Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care
NCT05205928 on ClinicalTrials.gov · last registry update 2025-01-22
A small phase 2/phase 3 — 28 participants, against a typical 60. The sponsor logged completion for 15 April 2024. Primary outcome, as filed: Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo). semaglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2/P3
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Sponsor type
- Other
- Enrollment
- 28
- Started
- 2022-10-02
- Primary completion
- 2024-04-15 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage of time of plasma glucose levels spent in target range (semaglutide vs placebo)
Conditions studied
Type 1 Diabetes · Diabetes Mellitus, Type 1
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.